<DOC>
	<DOC>NCT02974270</DOC>
	<brief_summary>Analysis of body mass index in Central Precocious Puberty patients treated with leuprolide acetate</brief_summary>
	<brief_title>Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate</brief_title>
	<detailed_description />
	<mesh_term>Puberty, Precocious</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1. Child diagnosed with CPP who has a peakstimulated Lutenizing Hormone(LH) concentration over 5 IU/liter before initiation of therapy 2. Chronological age(CA) at the appearance of pubertal changes less than 8 years in girls and less than 9 years in boys. 3. Tanner stage â‰¥2 4. Advanced bone age (Bone Age/Chronological Age &gt;1.1) 5. Able to have the signed written informed consent provided by the patients' parents or legal guardians prior to any studyrelated procedures 1. Patient with a peripheral precocious puberty: extrapituitary secretion of gonadotropins or gonadotropinindependent gonadal or adrenal sex steroids secretion 2. Patient with a cerebral tumor requiring a neurosurgery or cerebral irradiation known chronic disease of underlying medical condition 3. Currently on or planning growth hormone treatment 4. Previous GonadotropinReleasing Hormone agonist treatment 5. Any patient who in opinion of the investigator should not participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>